Table 1.
Adenocarinoma | Nonadenocarcinoma | P | |
---|---|---|---|
n = 218 | n = 148 | ||
Age (median [range]) | 63.00 [31.00, 87.00] | 64.00 [33.00, 88.00] | 0.53 |
Male gender (%) | 120 (55) | 79 (53) | 0.84 |
Number of brain metastases (%) | 0.22 | ||
1 | 106 (49) | 83 (56) | |
2 | 45 (21) | 34 (23) | |
3 | 34 (16) | 17 (12) | |
4 + | 33 (15) | 14 (9.5) | |
Systemic disease burden (%) | 0.52 | ||
None | 49 (23) | 31 (21) | |
Oligometastatic | 107 (49) | 80 (54) | |
Unknown | 4 (1.8) | 5 (3.4) | |
Widespread | 58 (27) | 32 (22) | |
Systemic disease status (%) | 0.40 | ||
Progressive | 71 (33) | 44 (30) | |
Stable | 132 (61) | 88 (60) | |
Unknown | 15 (6.9) | 16 (11) | |
KPS (%) | 0.30 | ||
50 | 1 (0.50) | 0 (0.0) | |
60 | 14 (6.4) | 16 (11) | |
70 | 34 (16) | 18 (12) | |
80 | 96 (44) | 69 (47) | |
90 | 69 (32) | 39 (26) | |
100 | 4 (1.8) | 6 (4.1) | |
DSGPA (%) | 0.47 | ||
0 | 3 (1.4) | 0 (0.0) | |
0.5 | 9 (4.1) | 10 (6.8) | |
1 | 41 (19) | 28 (19) | |
1.5 | 65 (30) | 41 (28) | |
2 | 37 (17) | 29 (20) | |
2.5 | 34 (16) | 23 (16) | |
3 | 22 (10) | 9 (6.1) | |
3.5 | 6 (2.8) | 8 (5.4) | |
4 | 1 (0.50) | 0 (0.0) | |
Smoking Status (%) | 0.40 | ||
Current | 77 (36) | 60 (41) | |
Noncurrent | 135 (62) | 88 (59) | |
Unknown | 2 (0.90) | 0 (0.0) | |
Pack years (median [IQR]) | 40 [20, 50] | 40 [20, 50] | 0.60 |
Metastasis number (median [range]) | 2.00 [1.00, 13.00] | 1.00 [1.00, 18.00] | 0.074 |
Minimal_dose (median [range]) | 20.00 [11.00, 24.00] | 20.00 [10.00, 24.00] | 0.71 |
KPS, Karnofsky performance status; DS‐GPA, disease‐specific Graded Prognostic Assessment.